ExCellThera has recently obtained conditional marketing authorization from the European Commission (EC) for its Zemcelpro cell therapy, designed to address the needs of adults with haematological malignancies requiring allogeneic stem cell transplants. This approval, granted to ExCellThera’s subsidiary, Cordex Biologics, signifies a significant advancement in providing treatment for blood cancer patients who lack suitable donor cells. Zemcelpro aims to offer a transplant solution for individuals with haematological malignancies necessitating allogeneic haematopoietic stem cell transplantation post-myeloablative conditioning.
The authorization from the EC allows for the distribution of Zemcelpro not only within the European Union (EU) member states but also in Iceland, Norway, and Liechtenstein. Zemcelpro, also known as UM171 Cell Therapy, is a unique treatment that combines UM171-expanded CD34+ cells with unexpanded CD34- cells from the same cord blood unit. By leveraging this approach, Zemcelpro intends to broaden access to life-saving transplants, potentially alleviating the healthcare burdens associated with blood cancers. This development is a crucial step towards fulfilling the therapeutic promise of Zemcelpro in aiding adults combatting life-threatening haematological malignancies.
The recommendation from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) in June 2025 played a pivotal role in securing the EC approval for Zemcelpro. The CHMP’s positive evaluation was based on data from two Phase II clinical studies demonstrating Zemcelpro’s efficacy in inducing neutrophil and platelet engraftment. Cordex Biologics, the company behind Zemcelpro, conducted extensive trials involving 120 patients across the US, Europe, and Canada, leading to regulatory recognitions such as orphan drug status from the US FDA and PRIME designation from the EMA.
Looking ahead, ExCellThera plans to submit Zemcelpro for regulatory review in the US, the UK, Canada, and Switzerland. The company is actively engaging with national health authorities to expedite patient access to Zemcelpro prior to the completion of reimbursement processes. The availability of Zemcelpro in the future hinges on the outcomes of national reimbursement evaluations, with a Phase III trial targeting high-risk acute leukaemias and myelodysplasias in the pipeline. Notably, the safety profile of Zemcelpro aligns with traditional allogeneic stem cell transplantation methods, underscoring its potential as a safe and effective treatment option.
In conclusion, the EC authorization for ExCellThera’s Zemcelpro cell therapy represents a significant milestone in advancing treatment options for individuals with haematological malignancies lacking suitable donor cells. By navigating regulatory pathways and conducting robust clinical trials, ExCellThera and Cordex Biologics are paving the way for improved access to life-saving transplants and renewed hope for patients facing challenging blood cancer diagnoses.
- Regulatory approvals mark key milestones in advancing innovative cell therapies
- Extensive clinical trials are essential to demonstrate safety and efficacy for regulatory submissions
- Strategic engagement with national health authorities can expedite patient access to novel treatments
- Alignment with regulatory agencies’ recommendations is crucial for successful market authorization
Tags: regulatory submissions, cell therapy, gene therapy, regulatory
Read more on pharmaceutical-technology.com